Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases - An unrevealed role in downregulation of Th17 cells

Journal of Autoimmunity

Volumn 37, Issue 3, 2011, Pages 160-170

  Wang, Yen Ling ^a   Chou, Feng Cheng ^a   Chen, Shyi Jou ^b   Lin, Shih Hua ^b   Chang, Deh Ming ^b   Sytwu, Huey Kang ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Experimental autoimmune encephalomyelitis; NOD mice; Pre ligand assembly domain; Th17

Indexed keywords

INTERLEUKIN 6; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; TH1 CELL; TH17 CELL;

ANIMALS; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS, TYPE 1; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; INTERLEUKIN-6; JURKAT CELLS; MICE; MICE, INBRED NOD; MOLECULAR TARGETED THERAPY; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TH17 CELLS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 80755140041     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.05.013     Document Type: Article

References (65)

1. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.
2. Siegel R.M., Frederiksen J.K., Zacharias D.A., Chan F.K., Johnson M., Lynch D., et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000, 288:2354-2357.
3. Siegel R.M., Chan F.K., Chun H.J., Lenardo M.J. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000, 1:469-474.
4. Chan K.F., Siegel M.R., Lenardo J.M. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000, 13:419-422.
5. Chan F.K. The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. Ann Rheum Dis 2000, 59(Suppl. 1):50-53.
6. Chan F.K. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 2007, 37:101-107.
7. Deng G.M., Zheng L., Chan F.K., Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 2005, 11:1066-1072.
8. Ross S.E., Williams R.O., Mason L.J., Mauri C., Marinova-Mutafchieva L., Malfait A.M., et al. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997, 159:6253-6259.
9. Liu Z., Jiu J., Liu S., Fa X., Li F., Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. J Autoimmun 2007, 29:187-194.
10. Chen K., Wei Y., Sharp G.C., Braley-Mullen H. Decreasing TNF-alpha results in less fibrosis and earlier resolution of granulomatous experimental autoimmune thyroiditis. J Leukoc Biol 2007, 81:306-314.
11. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suarez-Farinas M., Fuentes-Duculan J., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183-3194.
12. Yang X.D., Tisch R., Singer S.M., Cao Z.A., Liblau R.S., Schreiber R.D., et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994, 180:995-1004.
13. McDevitt H., Munson S., Ettinger R., Wu A. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 2002, 4(Suppl. 3):S141-S152.
14. Hunger R.E., Carnaud C., Garcia I., Vassalli P., Mueller C. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur J Immunol 1997, 27:255-261.
15. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998, 14:129-151.
16. Matsuda T., Omori K., Vuong T., Pascual M., Valiente L., Ferreri K., et al. Inhibition of p38 pathway suppresses human islet production of pro-inflammatory cytokines and improves islet graft function. Am J Transplant 2005, 5:484-493.
17. Rabinovitch A., Suarez-Pinzon W.L., Sorensen O., Rajotte R.V., Power R.F. TNF-alpha down-regulates type 1 cytokines and prolongs survival of syngeneic islet grafts in nonobese diabetic mice. J Immunol 1997, 159:6298-6303.
18. Delovitch T.L., Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997, 7:727-738.
19. Chou F.C., Shieh S.J., Sytwu H.K. Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. Eur J Immunol 2009, 39:2403-2411.
20. Emamaullee J.A., Davis J., Merani S., Toso C., Elliott J.F., Thiesen A., et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009, 58:1302-1311.
21. Martin-Orozco N., Chung Y., Chang S.H., Wang Y.H., Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 2009, 39:216-224.
22. Jain R., Tartar D.M., Gregg R.K., Divekar R.D., Bell J.J., Lee H.H., et al. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med 2008, 205:207-218.
23. Sung H.H., Juang J.H., Lin Y.C., Kuo C.H., Hung J.T., Chen A., et al. Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J Exp Med 2004, 199:1143-1151.
24. Chen S.J., Wang Y.L., Kao J.H., Wu S.F., Lo W.T., Wu C.C., et al. Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells. Mol Immunol 2009, 47:567-574.
25. Rabinovitch A., Suarez-Pinzon W.L., Sorensen O., Bleackley R.C., Power R.F. IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J Immunol 1995, 154:4874-4882.
26. Trembleau S., Penna G., Bosi E., Mortara A., Gately M.K., Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995, 181:817-821.
27. Katz J.D., Benoist C., Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995, 268:1185-1188.
28. Vukkadapu S.S., Belli J.M., Ishii K., Jegga A.G., Hutton J.J., Aronow B.J., et al. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics 2005, 21:201-211.
29. Bending D., De La Pena H., Veldhoen M., Phillips J.M., Uyttenhove C., Stockinger B., et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009, 119:565-572.
30. Gottlieb A.B., Chamian F., Masud S., Cardinale I., Abello M.V., Lowes M.A., et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005, 175:2721-2729.
31. Christen U., Wolfe T., Mohrle U., Hughes A.C., Rodrigo E., Green E.A., et al. A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis. J Immunol 2001, 166:7023-7032.
32. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
33. Harrington L.E., Mangan P.R., Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006, 18:349-356.
34. Aranami T., Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008, 57:115-120.
35. Lee L.F., Xu B., Michie S.A., Beilhack G.F., Warganich T., Turley S., et al. The role of TNF-alpha in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic cell maturation. Proc Natl Acad Sci U S A 2005, 102:15995-16000.
36. + dendritic cells evoking Th1 and Th17 responses. J Immunol 2007, 179:1449-1457.
37. Hultgren B., Huang X., Dybdal N., Stewart T.A. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996, 45:812-817.
38. Trembleau S., Penna G., Gregori S., Giarratana N., Adorini L. IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma. J Immunol 2003, 170:5491-5501.
39. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007, 13:423-431.
40. Pakala S.V., Chivetta M., Kelly C.B., Katz J.D. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 1999, 189:1053-1062.
41. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997, 337:141-147.
42. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
43. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
44. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
45. Roberts L., McColl G.J. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 2004, 34:687-693.
46. Nash P.T., Florin T.H. Tumour necrosis factor inhibitors. Med J Aust 2005, 183:205-208.
47. Suvannavejh G.C., Lee H.O., Padilla J., Dal Canto M.C., Barrett T.A., Miller S.D. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol 2000, 205:24-33.
48. Eugster H.P., Frei K., Bachmann R., Bluethmann H., Lassmann H., Fontana A. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 1999, 29:626-632.
49. Peschon J.J., Torrance D.S., Stocking K.L., Glaccum M.B., Otten C., Willis C.R., et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998, 160:943-952.
50. + T regulatory cells. J Immunol 2007, 179:154-161.
51. Grinberg-Bleyer Y., Saadoun D., Baeyens A., Billiard F., Goldstein J.D., Gregoire S., et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest 2010, 120:4558-4568.
52. Bilate A.M., Lafaille J.J. Can TNF-alpha boost regulatory T cells?. J Clin Invest 2010, 120:4190-4192.
53. Korner H., Goodsall A.L., Lemckert F.A., Scallon B.J., Ghrayeb J., Ford A.L., et al. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 1995, 92:11066-11070.
54. Klinkert W.E., Kojima K., Lesslauer W., Rinner W., Lassmann H., Wekerle H. TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997, 72:163-168.
55. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis GroupThe University of British Columbia MS/MRI Analysis Group.
56. Cope A., Ettinger R., McDevitt H. The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997, 148:307-312.
57. Klareskog L., McDevitt H. Rheumatoid arthritis and its animal models: the role of TNF-alpha and the possible absence of specific immune reactions. Curr Opin Immunol 1999, 11:657-662.
58. Green E.A., Flavell R.A. Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice. Immunol Rev 1999, 169:11-22.
59. Theofilopoulos A.N., Lawson B.R. Tumour necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 1999, 58(Suppl. 1):I49-I55.
60. Kollias G., Douni E., Kassiotis G., Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 1999, 58(Suppl. 1):I32-I39.
61. Kramer J.M., Yi L., Shen F., Maitra A., Jiao X., Jin T., et al. Evidence for ligand-independent multimerization of the IL-17 receptor. J Immunol 2006, 176:711-715.
62. Kramer J.M., Hanel W., Shen F., Isik N., Malone J.P., Maitra A., et al. Cutting edge: identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptor. J Immunol 2007, 179:6379-6383.
63. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006, 116:1317-1326.
64. Lubberts E., Koenders M.I., van den Berg W.B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005, 7:29-37.
65. Kikly K., Liu L., Na S., Sedgwick J.D. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006, 18:670-675.